TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2026)

TransMedics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 71.32% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 36.22% YoY), and the FY2025 full-year result was $1.1 billion, up 32.87% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.4 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.4 billion in Q1 2026, with the low at $117.3 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $671.5 million, with a median of $723.8 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity fell 16.53% in 2022 and surged 488.62% in 2023.
• Tracing TMDX's Liabilities and Shareholders Equity over 5 years: stood at $277.1 million in 2022, then jumped by 154.76% to $706.0 million in 2023, then gained by 13.88% to $804.1 million in 2024, then soared by 32.87% to $1.1 billion in 2025, then soared by 34.3% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $946.0 million (Q3 2025), per Business Quant data.

Peer Comparison